Abstract
Sport psychiatry focuses on diagnosis and treatment of psychiatric illness in athletes in addition to utilization of psychological approaches to enhance performance. As this field and its research base are relatively new, clinicians often deliver psychiatric care to athletes without a full understanding of the diagnostic and therapeutic issues unique to this population. In this systematic review, we discuss published findings relating to psychiatric diagnosis and medical treatment of mental illness in athletes.
There have been several studies looking at the prevalence of some psychiatric disorders in various athlete populations. Eating disorders and substance abuse are the most studied of these disorders and appear to be common problems in athletes. However, to provide informed understanding and treatment, we especially need more research on overtraining syndrome, bipolar disorder, suicidality, anxiety disorders, attention-deficit hyperactivity disorder (ADHD) and psychosis in athletes. Research is needed in the areas of prevalence, risk factors, prognosis and the unique experiences facing athletes with any of these disorders.
Additionally, there have not been any large, systematic studies on the use of psychotropic medications in athletes. Small studies suggest that some medications may either be performance enhancing or detrimental to performance, but we need larger studies with rigorous methodology. Higher level athletes suffering from psychiatric symptoms often have reservations about taking medications with unknown performance and safety effects, and methodological issues with the current literature database preclude any definitive conclusions on performance effects of psychiatric medications. We need many more, higher quality studies on the use by athletes of antidepressants, mood stabilizers, anxiolytics, stimulants and other ADHD medications, sedative-hypnotics and antipsychotics. Such studies should utilize sensitive performance measures and involve longer term use of psychotropic medications. Furthermore, study subjects should include athletes who actually have the psychiatric disorder for which the medication is proposed, and should include more women.
Similar content being viewed by others
References
Begel D. Family systems-based treatment of the athlete family. In: Begel D, Burton RW, editors. Sport psychiatry. New York (NY): WW Norton & Company, Inc., 2000: 206–28
Glick ID, Kamm R, Morse E. The evolution of sport psychiatry, circa 2009. Sports Med 2009; 39 (8): 607–13
Hellstedt J. Invisible players: a family systems model. Clin Sports Med 2005; 24 (4): 899–928
McDuff DR, Morse ED, White RK. Professional and collegiate team assistance programs: services and utilizationpatterns. Clin Sports Med 2005; 24 (4): 943–58
Kamm RL. The sport psychiatry examination. In: Begel D, Burton RW, editors. Sport psychiatry. New York (NY): WW Norton & Company, Inc., 2000: 159–90
Glick ID, Horsfall JL. Diagnosis and psychiatric treatment of athletes. Clin Sports Med 2005; 24 (4): 771–81
Baum AL. Sport psychiatry: how to keep athletes in the game of life, on or off the field. Curr Psychiatry 2003; 2 (1): 51–6
Baum AL. Psychopharmacology in athletes. In: Begel D, Burton RW, editors. Sport psychiatry. New York (NY): WW Norton & Company, Inc., 2000: 249–59
Burton RW. Mental illness in athletes. In: Begel D, Burton RW, editors. Sport psychiatry. New York (NY): WWNorton & Company, Inc., 2000: 61–81
Oler MJ, Mainous AG, Martin CA, et al. Depression, suicidal ideation, and substance use among adolescents: areathletes at less risk? Arch Fam Med 1994; 3: 781–3
Yang J, Peek-Asa C, Corlette JD, et al. Prevalence of and risk factors associated with symptoms of depression incompetitive collegiate student athletes. Clin J Sport Med 2007; 17 (6): 481–7
Puffer JC, McShane JM. Depression and chronic fatigue in the college student-athlete. Prim Care 1991; 18 (2): 297–308
Donohue B, Covassin T, Lancer K. Examination of psychiatric symptoms in student athletes. J Gen Psychol 2004; 131: 29–36
Rosen LW, Smokler C, Carrier D, et al. Seasonal mood disturbances in collegiate hockey players. J Athl Train 1996; 31 (3): 225–8
Kasper S, Rogers SLB, Yancey A, et al. Phototherapy in individuals with and without subsyndromal seasonal affectivedisorder. Arch Gen Psychiatry 1989; 46: 837–44
Macleod AD. Sport psychiatry. Aust N Z J Psychiatry 1998; 32: 860–6
Armstrong LE, VanHeest JL. The unknown mechanism of the overtraining syndrome: clues from depression andpsychoneuroimmunology. Sports Med 2002; 32: 185–209
Morgan WP, Brown DR, Raglin JS, et al. Psychological monitoring of overtraining and staleness. Br J Sports Med 1987; 21 (3): 107–14
Schwenk TL. The stigmatization and denial of mental illness in athletes. Br J Sports Med 2000; 34 (1): 4–5
McCann S. Overtraining and burnout. In: Murphy SM, editor. Sport psychology interventions. Champaign (IL): Human Kinetics, 1995: 347–65
Callister R, Callister RK, Fleck SJ, et al. Physiological and performance responses to overtraining in elite judo athletes. Med Sci Sports Exerc 1989; 22: 816–24
Costill DL, Flynn MG, Kirwin JP, et al. Effects of repeated days of intensified training on muscle glycogen andswimming performance. Med Sci Sports Exerc 1998; 20: 249–54
Hackney AC, Pearman SN, Nowacki JM. Physiological profiles of overtrained and stale athletes: a review. Appl Sport Psychol 1990; 2: 21–33
Parham WD. The intercollegiate athlete: a 1990s profile. Couns Psychol 1993; 21: 411–29
Backmand H, Kaprio J, Kujala U, et al. Influence of physical activity on depression and anxiety of former eliteathletes. Int J Sports Med 2003; 24: 609–16
Schwenk TL, Gorenflo DW, Dopp RR, et al. Depression and pain in retired professional football players. Med Sci Sports Exerc 2007; 39 (4): 599–605
Baum AL. Suicide in athletes: a review and commentary. Clin Sports Med 2005; 24 (4): 853–69
Smith AM, Milliner EK. Injured athletes and the risk of suicide. J Athl Train 1987; 29: 337–41
Smith AM, Scott SG, Wiese DM. The psychological effects of sports injuries: coping. Sports Med 1990; 9: 353–69
Begel D. The psychopathology of everyday athletic life. In: Begel D, Burton RW, editors. Sport psychiatry. New York (NY): WW Norton & Company, Inc., 2000: 82–92
Kamm RL. Interviewing principles for the psychiatrically aware sports medicine physician. Clin Sports Med 2005; 24 (4): 745–69
Northon PJ, Burns JA, Hope DA. Generalization of social anxiety to sporting and athletic situations: gender, sportsinvolvement, and parental pressure. Depress Anxiety 2000; 12: 193–202
Glasser W. Positive addiction. New York (NY): Harper and Row, 1976
Sachs ML, Pargman D. Running addiction: a depth interview examination. J Sport Behav 1979; 2: 143–55
Yates A, Leehey K, Shisslak CM. Running: an analogue of anorexia? N Engl J Med 1983; 308 (5): 251–5
Pope H, Gruber A, Choi P, et al. Muscle dysmorphia: an underrecognized form of body dysmorphic disorder. Psychosomatics 1997; 38: 548–57
Calhoun JW, Ogilvie BC, Hendrickson TP, et al. The psychiatric consultant in professional team sports. Child Adolesc Psychiatr Clin N Am 1998; 7 (4): 791–802
Rosen LW, McKeag DB, Hough DO, et al. Pathogenic weight-control behavior in female athletes. Phys Sportsmed 1986; 14 (1): 79–86
Burckes-Miller ME, Black DR. Behaviors and attitudes associated with eating disorders: perceptions of collegeathletes about food and weight. Health Educ Res 1988; 3: 203–8
Byrne S, McLean N. Elite athletes: effects of the pressure to be thin. J Sci Med Sport 2002; 5: 80–94
Torstveit MK, Rosenvinge JH, Sundgot-Borgen J. Prevalence of eating disorders and the predictive power ofrisk models in female elite athletes: a controlled study. Scand J Med Sci Sports 2008; 18: 108–18
Sundgot-Borgen J, Torstveit MK. Prevalence of eating disorders in elite athletes is higher than in the generalpopulation. Clin J Sport Med 2004; 14: 25–32
Thiel A, Gottfried H, Hesse FW. Subclinical eating disorders in male athletes: a study of the low weight categoryin rowers and wrestlers. Acta Psychiat Scand 1993; 88: 259–65
Glazer JL. Eating disorders among male athletes. Curr Sports Med Rep 2008; 7 (6): 332–7
Swoop RA, Murphy SM. Eating disorders and weight management in athletes. In: Murphy SM, editor. Sport psychology interventions. Champaign (IL): Human Kinetics, 1995: 307–26
Johnson LD, O’Malley PM, Bachman JG, et al. Monitoring the future national survey on drug use, 1975–2003, Vol. II. College students and adults ages 19-25. NIH publication no. 04-5508. Bethesda (MD): National Instituteon Drug Abuse, 2004
Green GA, Uryasz FD, Petr TA, et al. NCAA study of substance abuse habits of college student-athletes. Clin JSport Med 2001; 11 (1): 51–6
O’Brien CP. Alcohol and sport: impact of social drinking on recreational and competitive sports performance. Sports Med 1993; 15: 71–7
Miller BE, Miller MN, Verhegge R, et al. Alcohol misuse among college athletes: self-medication for psychiatric symptoms? J Drug Education 2002; 32 (1): 41–52
McDuff DR, Baron D. Substance use in athletics: a sports psychiatry perspective. Clin Sports Med 2005; 24: 885–97
Su TP, Pagliaro M, Schmidt PJ, et al. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993; 269: 2760–4
Moss HB, Panzak GL. Steroid use and aggression [letter]. Am J Psychiatry 1992; 149: 1616
Pope HG, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160athletes. Arch Gen Psychiatry 1994; 51: 375–82
Kerber CS. Problem and pathological gambling among college athletes. Ann Clin Psychiatry 2005; 17 (4): 243–7
Lesieur HR, Rosenthal RJ. Pathological gambling: a review of the literature (prepared for the American Psychiatric Association Task Force on DSM-IV. Committeeon Disorders of Impulse Control Not Elsewhere Classified). J Gambling Stud 1991; 7: 5–39
Miller TW, Adams JM, Kraus RF, et al. Gambling as an addictive disorder among athletes: clinical issues in sportsmedicine. Sports Med 2001; 31 (3): 145–52
Cantu RC. Prevention of athletic injuries: the role of the sports medicine team. In: Mueller FO, Ryan AJ, editors. Head and neck injuries. Philadelphia (PA): FA Davis, 1991: 201–13
Broshek DK, Barth JT. Neuropsychological assessment of the amateur athletes. In: Bailes J, Day A, editors. Neurological sports medicine: a guide for physicians andathletic trainers. Rolling Meadows (IL): The AmericanAssociation of Neurological Surgeons, 2001: 155–68
Freeman JR, Barth JT, Broshek DK. Sports injuries. In: Silver JM, McAllister TW, Yudofsky SC, editors. Textbookof traumatic brain injury. Washington, DC: American Psychiatric Publishing, 2001: 453–76
Broshek DK, Kaushik T, Freeman JR. Gender differences in outcome from sports-related concussion. J Neurosurg 2005; 102: 856–63
World Anti-Doping Agency [online]. Available from URL: http://www.wada-ama.org/en/ [Accessed 2009 Aug 13]
Blomstrand E, Celsing F, Newsholme E. Changes in plasma levels of aromatic and branched chain amino acids duringsustained exercise in man and their possible role in fatigue. Acta Physiol Scand 1988; 133: 115–21
Blomstrand E, Hassmen P, Ekblom B, et al. Administration of branched chain amino acids during sustainedexercise-effects on performance and on plasma concentrationof some amino acids. Eur J Appl Physiol 1991; 63: 83–8
Blomstrand E, Hassmen P, Newsholme E. Effect of branched chain amino acid supplementation on mental performance. Acta Physiol Scand 1991; 143: 225–6
Roelands B, Hasegawa H, Watson P, et al. The effects of acute dopamine reuptake inhibition on performance. Med Sci Sports Exercise 2008; 40 (5): 879–85
Parise G, Bosman MJ, Boecker DR. Selective serotonin reuptake inhibitors: their effect on high-intensity exerciseperformance. Arch Phys Med Rehabil 2001; 82: 867–71
Meeusen R, Piacentini MF, van Den Eynde S, et al. Exercise performance is not influenced by a 5-HT reuptakeinhibitor. Int J Sports Med 2001; 22: 329–36
Wilson WM, Maughan RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man:administration of paroxetine, a 5-HT re-uptake inhibitor,reduces the capacity to perform prolonged exercise. Exp Physiol 1992; 77: 921–4
Strachan AT, Leiper JB, Maughan RJ. Paroxetine administration fails to influence human exercise capacity, perceivedeffort or hormone responses during prolonged exercise in awarm environment. Exp Physiol 2004; 89.6: 657–64
Piacentini MF, Meeusen R, Buyse L, et al. Hormonal responses during prolonged exercise are influenced by a selectiveDA/NA reuptake inhibitor. Br J Sports Med 2004; 38: 129–33
Watson P, Hasegawa H, Roelands B, et al. Acute dopamine/ noradrenaline reuptake inhibition enhances humanexercise performance in warm, but not temperate conditions. J Physiol 2005; 565.3: 873–83
Roelands B, Hasegawa H, Watson P, et al. Performance and thermoregulatory effects of chronic bupropion administrationin the heat. Eur J Appl Physiol 2009; 105 (3): 493–8
Piacentini MF, Meeusen R, Buyse L, et al. No effect of a noradrenergic reuptake inhibitor on performance intrained cyclists. Med Sci Sports Exercise 2002; 34 (7): 1189–93
Roelands B, Goekint M, Heyman E, et al. Acute noradrenaline reuptake inhibition decreases performance innormal and high ambient temperature. J Appl Physiol 2008; 105 (1): 206–12
Fowler NO, McCall D, Chou T-C, et al. Electrocardiographic changes and cardiac arrhythmias in patients receivingpsychotropic drugs. AmJ Cardiol 1976; 37: 223–30
Waslick BD, Walsh BT, Greenhill LL, et al. Cardiovascular effects of desipramine in children and adultsduring exercise testing. J Am Acad Child Adolesc Psychiatry 1999; 38 (2): 179–86
de Zwaan M. Exercise and antidepressant serum levels. Biol Psychiatry 1992; 32: 210–11
Smith DF. The effect of exercise and pain-stress on the renal clearance of lithium, sodium, potassium, and creatininein the rat. Int Pharmacopsychiatry 1973; 8: 217–20
Miller EB, Pain RW, Skripal PJ. Sweat lithium in manicdepression. Br J Psychiatry 1978; 133: 477–8
Jefferson JW, Greist JH, Clagnaz PJ, et al. Effect of strenuous exercise on serum lithium level in man. Am J Psychiatry 1982; 139 (12): 1593–5
Tilkian AG, Schroeder JS, Kao J, et al. Effect of lithium on cardiovascular performance: report on extended ambulatorymonitoring and exercise testing before and duringlithium therapy. Am J Cardiol 1976; 38: 701–8
Cowan DA. Drug abuse. In: Harries M, Williams C, Stanish WD et al., editors. Oxford textbook of sports medicine. New York (NY): Oxford University Press, 1994: 314–29
Wilmore JH. Exercise testing, training, and beta-adrenergic blockade. Phys Sportsmed 1988; 16: 45–50
Schwenk TL. Psychoactive drugs and athletic performance. Phys Sportsmed 1997; 25 (1): 33–46
Marvin G, Sharma A, Aston W, et al. The effects of buspirone on perceived exertion and time to fatigue in man. Exp Physiol 1997; 82: 1057–60
Kennedy M. Drugs and Athletes: an update. Adverse Drug React Bull 1994; 169: 639–42
Smith GM, Beecher HK. Amphetamine sulfate and athletic performance. I: objective effects. JAMA 1959; 170: 542–57
Chandler JV, Blair SN. The effect of amphetamines on selected physiological components related to athletic success. Med Sci Sports Exerc 1980; 12 (1): 65–9
Shaikin B. Baseball’s 2008 drug test results released in report. Los Angeles Times, 2009 Jan 10 [online]. Available from URL: http://articles.latimes.com/2009/jan/10/sports/sp-newswire10 [Accessed 2010 Sep 17]
Hickey G, Fricker P. Attention deficit hyperactivity disorder, CNS stimulants, and sport. Sports Med 1999; 27 (1): 11–21
Conant-Norville DO, Tofler I. Attention deficit/hyperactivity disorder and psychopharmacologic treatments in theathlete. Clin Sports Med 2005; 24 (4): 829–43
Atkinson G, Drust B, Reilly T, et al. The relevance of melatonin to sports medicine and science. Sports Med 2003; 33 (11): 809–31
Gonzalez-Alonso J, Teller C, Andersen SL, et al. Influence of body temperature on the development of fatigue duringprolonged exercise in the heat. J Appl Physiol 1999; 86: 1032–9
Walters TJ, Ryan KL, Tate LM, et al. Exercise in the heat is limited by a critical internal temperature. J Appl Physiol 2000; 89: 799–806
Reilly T, Atkinson G, Budgett R. Effect of low-dose temazepam on physiological variables and performance tests following a westerly flight across five time zones. IntJ Sports Med 2001; 22: 166–74
Ito SU, Kanbayashi T, Takemura T, et al. Acute effects of zolpidem on daytime alertness, psychomotor and physicalperformance. Neurosci Res 2007; 59: 309–13
Holmberg G. The effects of anxiolytics on CFF. Pharmacopsychiatry 1982; 15 Suppl.: 49–53
Maddock RJ, Casson EJ, Lott LA, et al. Benzodiazepine effects on flicker sensitivity: role of stimulus frequencyand size. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 955–70
Mougin F, Bourdin H, Simon-Rigaud ML, et al. Hormonal responses to exercise after partial sleep deprivationand after a hypnotic drug-induced sleep. J Sports Sci 2001; 19: 89–97
Tafti M, Besset A, Billiard M. Effects of zopiclone on subjective evaluation of sleep and daytime alertness and onpsychomotor and physical performance tests in athletes. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 55–63
Grobler LA, Schwellnus MP, Trichard C, et al. Comparative effects of zopiclone and loprazolam on psychomotorand physical performance in active individuals. Clin JSport Med 2000; 10 (2): 123–8
Paul MA, Gray G, Kenny G, et al. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med 2003; 74 (12): 1263–70
Charles RB, Kirkham AJT, Guyatt AR, et al. Psychomotor, pulmonary and exercise responses to sleep medication. Br J Clin Pharmac 1987; 24: 191–7
Acknowledgements
The authors report no funding for the preparation of this review and no relevant conflicts of interest. Both authors made substantial contributions to this work and meet criteria for authorship. We thank the anonymous reviewers of this manuscript for their very helpful suggestions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reardon, C.L., Factor, R.M. Sport Psychiatry. Sports Med 40, 961–980 (2010). https://doi.org/10.2165/11536580-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11536580-000000000-00000